Related references
Note: Only part of the references are listed.Plasma neurofilament light chain concentration in the inherited peripheral neuropathies
Asa Sandelius et al.
NEUROLOGY (2018)
Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases
Filippo Baldacci et al.
EXPERT REVIEW OF PROTEOMICS (2017)
Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis
Lauren M. Byrne et al.
LANCET NEUROLOGY (2017)
Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer's disease and down syndrome
Harutsugu Tatebe et al.
MOLECULAR NEURODEGENERATION (2017)
Soluble TREM2 in CSF sheds light on microglial activation in AD
Heather Wood
Nature Reviews Neurology (2017)
Neurogranin, a synaptic protein, is associated with memory independent of Alzheimer biomarkers
Kaitlin B. Casaletto et al.
NEUROLOGY (2017)
Serum neurofilament light in familial Alzheimer disease A marker of early neurodegeneration
Philip S. J. Weston et al.
NEUROLOGY (2017)
Review: Tau in biofluids - relation to pathology, imaging and clinical features
H. Zetterberg
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2017)
Development of a Biochemical Diagnosis of Parkinson Disease by Detection of α-Synuclein Misfolded Aggregates in Cerebrospinal Fluid
Mohammad Shahnawaz et al.
JAMA NEUROLOGY (2017)
Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging
Michelle M. Mielke et al.
JAMA NEUROLOGY (2017)
Comparing Plasma Phospho Tau, Total Tau, and Phospho Tau-Total Tau Ratio as Acute and Chronic Traumatic Brain Injury Biomarkers
Richard Rubenstein et al.
JAMA NEUROLOGY (2017)
Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis
Vitaliy Ovod et al.
ALZHEIMERS & DEMENTIA (2017)
CSF Aβ1-42 - an excellent but complicated Alzheimer's biomarker - a route to standardisation
Julia Kuhlmann et al.
CLINICA CHIMICA ACTA (2017)
Immediate initiation of cART is associated with lower levels of cerebrospinal fluid YKL-40, a marker of microglial activation, in HIV-1 infection
Michael J. Peluso et al.
AIDS (2017)
Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies
Toshiki Uchihara et al.
ACTA NEUROPATHOLOGICA (2016)
Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status
Laura Piccio et al.
ACTA NEUROPATHOLOGICA (2016)
Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1-42) in human cerebrospinal fluid
Tobias Bittner et al.
ALZHEIMERS & DEMENTIA (2016)
CNS tau efflux via exosomes is likely increased in Parkinson's disease but not in Alzheimer's disease
Min Shi et al.
ALZHEIMERS & DEMENTIA (2016)
TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia
Bryan D. James et al.
BRAIN (2016)
Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa
Jens Kuhle et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2016)
sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers
Marc Suarez-Calvet et al.
EMBO MOLECULAR MEDICINE (2016)
Blood-Based Biomarker Candidates of Cerebral Amyloid Using PiB PET in Non-Demented Elderly
Sarah Westwood et al.
JOURNAL OF ALZHEIMERS DISEASE (2016)
Reference measurement procedure for CSF amyloid beta (Aβ)1-42 and the CSF Aβ1-42/Aβ1-40 ratio - a cross-validation study against amyloid PET
Josef Pannee et al.
JOURNAL OF NEUROCHEMISTRY (2016)
CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis
Bob Olsson et al.
LANCET NEUROLOGY (2016)
Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease
Amanda Heslegrave et al.
MOLECULAR NEURODEGENERATION (2016)
Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone
Annika Ohrfelt et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Predicting Alzheimer disease from a blood-based biomarker profile: A 54-month follow-up
Samantha C. Burnham et al.
NEUROLOGY (2016)
Increased CSF neurogranin concentration is specific to Alzheimer disease
Henrietta Wellington et al.
NEUROLOGY (2016)
Neurofilament Light: A Dynamic Cross-Disease Fluid Biomarker for Neurodegeneration
Henrik Zetterberg
NEURON (2016)
Clinical applications of MS-based protein quantification
Bassel Sabbagh et al.
PROTEOMICS CLINICAL APPLICATIONS (2016)
Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone
Annika Ohrfelt et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Plasma neurofilament light chain predicts progression in progressive supranuclear palsy
Julio C. Rojas et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2016)
Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies
Graham Fairfoul et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2016)
Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study
Magnus Gisslen et al.
EBIOMEDICINE (2016)
Plasma β-amyloid in Alzheimer's disease and vascular disease
Shorena Janelidze et al.
SCIENTIFIC REPORTS (2016)
Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease
Hlin Kvartsberg et al.
ALZHEIMERS & DEMENTIA (2015)
C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease
Ann De Vos et al.
ALZHEIMERS & DEMENTIA (2015)
Structural and functional features of central nervous system lymphatic vessels
Antoine Louveau et al.
NATURE (2015)
Plasma amyloid β-quo vadis?
Henrik Zetterberg
NEUROBIOLOGY OF AGING (2015)
Tissue-based map of the human proteome
Mathias Uhlen et al.
SCIENCE (2015)
Amyloid biomarkers in Alzheimer's disease
Kai Blennow et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2015)
Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer's disease patients and healthy controls
Hlin Kvartsberg et al.
ALZHEIMERS RESEARCH & THERAPY (2015)
Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease
Konstantin Hellwig et al.
ALZHEIMERS RESEARCH & THERAPY (2015)
Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease
Maartje I. Kester et al.
JAMA NEUROLOGY (2015)
TREM2 Protein Expression Changes Correlate with Alzheimer's Disease Neurodegenerative Pathologies in Post-Mortem Temporal Cortices
Lih-Fen Lue et al.
BRAIN PATHOLOGY (2015)
Blood Protein Markers of Neocortical Amyloid-beta Burden: A Candidate Study Using SOMAscan Technology
Nicola Voyle et al.
JOURNAL OF ALZHEIMERS DISEASE (2015)
Increased CSF α-synuclein levels in Alzheimer's disease: Correlation with tau levels
Sylvie Slaets et al.
ALZHEIMERS & DEMENTIA (2014)
Mass Spectrometry-Based Candidate Reference Measurement Procedure for Quantification of Amyloid-β in Cerebrospinal Fluid
Andreas Leinenbach et al.
CLINICAL CHEMISTRY (2014)
Qualification of a Surrogate Matrix-Based Absolute Quantification Method for Amyloid-beta(42) in Human Cerebrospinal Fluid Using 2D UPLC-Tandem Mass Spectrometry
Magdalena Korecka et al.
JOURNAL OF ALZHEIMERS DISEASE (2014)
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Bruno Dubois et al.
LANCET NEUROLOGY (2014)
The amyloid-β degradation pattern in plasma A possible tool for clinical trials in Alzheimer's disease
Josef Pannee et al.
NEUROSCIENCE LETTERS (2014)
Novel plasma biomarker surrogating cerebral amyloid deposition
Naoki Kaneko et al.
PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES (2014)
Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease
Oskar Hansson et al.
ALZHEIMERS RESEARCH & THERAPY (2014)
Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases
Emily Feneberg et al.
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2014)
Heterophilic antibody interference in immunometric assays
Nils Bolstad et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Microglial Markers are Elevated in the Prodromal Phase of Alzheimer's Disease and Vascular Dementia
Bob Olsson et al.
JOURNAL OF ALZHEIMERS DISEASE (2013)
Variant of TREM2 Associated with the Risk of Alzheimer's Disease
Thorlakur Jonsson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
TREM2 Variants in Alzheimer's Disease
Rita Guerreiro et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Low CSF Levels of Both α-Synuclein and the α-Synuclein Cleaving Enzyme Neurosin in Patients with Synucleinopathy
Malin Wennstrom et al.
PLOS ONE (2013)
The Diagnostic Value of CSF α-Synuclein in the Differential Diagnosis of Dementia with Lewy Bodies vs. Normal Subjects and Patients with Alzheimer's Disease
Elisabeth Kapaki et al.
PLOS ONE (2013)
Changes in Amyloid-β and Tau in the Cerebrospinal Fluid of Transgenic Mice Overexpressing Amyloid Precursor Protein
Luis F. Maia et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Plasma tau levels in Alzheimer's disease
Henrik Zetterberg et al.
ALZHEIMERS RESEARCH & THERAPY (2013)
Alpha-synuclein in the Cerebrospinal Fluid Differentiates Synucleinopathies (Parkinson Disease, Dementia With Lewy Bodies, Multiple System Atrophy) From Alzheimer Disease
Fuyuki Tateno et al.
ALZHEIMER DISEASE & ASSOCIATED DISORDERS (2012)
Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders
Sara Hall et al.
ARCHIVES OF NEUROLOGY (2012)
Chitinase enzyme activity in CSF is a powerful biomarker of Alzheimer disease
M. Watabe-Rudolph et al.
NEUROLOGY (2012)
A Paravascular Pathway Facilitates CSF Flow Through the Brain Parenchyma and the Clearance of Interstitial Solutes, Including Amyloid β
Jeffrey J. Iliff et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Current and Future Applications of Mass Spectrometry to the Clinical Laboratory
Frederick G. Strathmann et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2011)
Chemokines in CSF of Alzheimer's disease patients
Joice Dias Correa et al.
ARQUIVOS DE NEURO-PSIQUIATRIA (2011)
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study (vol 10, pg 230, 2011)
B. Mollenhauer et al.
LANCET NEUROLOGY (2011)
Cerebrospinal Fluid Microglial Markers in Alzheimer's Disease: Elevated Chitotriosidase Activity but Lack of Diagnostic Utility
Niklas Mattsson et al.
NEUROMOLECULAR MEDICINE (2011)
Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood
Martin Lundberg et al.
NUCLEIC ACIDS RESEARCH (2011)
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study
Brit Mollenhauer et al.
LANCET NEUROLOGY (2011)
YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease
Rebecca Craig-Schapiro et al.
BIOLOGICAL PSYCHIATRY (2010)
Quantification of alpha-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies
Brit Mollenhauer et al.
BIOMARKERS IN MEDICINE (2010)
DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease
Zhen Hong et al.
BRAIN (2010)
Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease
Annika Thorsell et al.
BRAIN RESEARCH (2010)
Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations
David M. Rissin et al.
NATURE BIOTECHNOLOGY (2010)
Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease
T. Tokuda et al.
NEUROLOGY (2010)
The Neuropathology of Probable Alzheimer Disease and Mild Cognitive Impairment
Julie A. Schneider et al.
ANNALS OF NEUROLOGY (2009)
Approaching clinical proteomics: current state and future fields of application in fluid proteomics
Rolf Apweiler et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2009)
Role of Soluble CD14 in Cerebrospinal Fluid as a Regulator of Glial Functions
Guo Nan Yin et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2009)
Cerebrospinal fluid α-synuclein in neurodegenerative disorders-A marker of synapse loss?
Annika Ohrfelt et al.
NEUROSCIENCE LETTERS (2009)
Red blood cells are the major source of alpha-synuclein in blood
Robin Barbour et al.
NEURODEGENERATIVE DISEASES (2008)
Stability of Pro-Gastrin-Releasing Peptide in Serum versus Plasma
Toru Yoshimura et al.
TUMOR BIOLOGY (2008)
Ultrasensitive flow-based immunoassays using single-molecule counting
John Todd et al.
CLINICAL CHEMISTRY (2007)
Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease
D Galimberti et al.
ARCHIVES OF NEUROLOGY (2006)
Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2
K Takahashi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Share Paper
